Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
20 results
D1.123 - Visualization of neutrophil extracellular traps (NETs) and autoantibodies targeting myeloperoxidase (MPO) and neutrophil elastase (NE) in sputum by confocal microscopy
D1.124 - Changes in respiratory infections patterns in Patients with Severe Asthma and a High burden of comorbidities treated with tezepelumab: interim analysis results of the T-ROSS II study
D1.126 - Therapeutic Splenic Ultrasound Insonation as a Modulator of Pro-atherogenic and Pro-asthmatic Immune Inflammation: A Preclinical Study Design
D1.128 - Use of Tezepelumab in four Patients with Allergic Bronchopulmonary Aspergillosis and severe uncontrolled Asthma: A Case Series
D1.130 - Immune markers after one year treatment with benralizumab in severe eosinophilic asthma
D1.131 - Unconventional Group 2 Innate Lymphoid Cells Expressing C-Kit and IL-17A are Increased in Sputum from Severe Asthma with Mixed Granulocytic Airway Inflammation
D2.326 - The frequency of hereditary α-tryptasemia (HαT) in patenits with insect venom anaphylaxis and in patients with mastocytosis – preliminary results
D2.324 - Anaphylaxis in very early childhood: An ongoing challenge
D2.325 - Desensitization of Olipudase alfa-induced anaphylaxis in a child with chronic neurovisceral acid sphingomyelinase deficiency and ochoa syndrome
D2.327 - Patient and caregiver perspectives on sublingual adrenaline for anaphylaxis: findings from an international survey
D2.329 - Profilin-mediated anaphylaxis with cofactor
D2.331 - An Adult Case of Cofactor-Induced Anaphylaxis Associated with Physical Exercise
D2.449 - Patients with Inadequately Controlled CRSwNP and Blood Eosinophil Count ≥150 cells/µL Experience Benefit with Depemokimab: An Analysis of Data from the Integrated ANCHOR-1/-2 Studies
D2.447 - Phenotyping of Chronic T2 Inflammatory Diseases of the Nose and Paranasal Sinuses and the Algorithm for Biologic Therapy Selection
D2.448 - Recommendations on Patient Education for Biological Therapy in CRSwNP – An EAACI Position Paper
D2.452 - Real-World Trends in the Epidemiology and Burden of Chronic Rhinosinusitis with Nasal Polyps Over Time in Germany Reveal Increasing Prevalence and Low Biologic Use
D2.455 - Does Biological Therapy Modify NSAID Hypersensitivity? Experience with Omalizumab and Mepolizumab in Patients with Asthma and Nasal Polyps with N-ERD
D2.456 - Chronic sinusitis with nasal polyposis: Add-on aspirin desensitization useful in dupilumab therapy?
D2.461 - Endothelial related miRs are dysregulated in C1-INH Angioedema patients: new potential biomarkers and therapeutic targets
D2.462 - Safety and predictors of tolerance in rituximab hypersensitivity management
Download the app
The congress at your fingertips
Available on
Download